Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing Non-Alcoholic Steatohepatitis
2024-518334-88-00Phase 4Authorised
- Sponsor
- Military University Hospital Prague
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of empagliflozin in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Military University Hospital Prague. Primary endpoint: Decrease of histological NASH activity. Planned start Oct 2024; status: authorised.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2024-518334-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518334-88-00.